Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects

@inproceedings{Nunes2010SafetyTA,
  title={Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects},
  author={T. de A. Nunes and Jos{\'e} Francisco Rocha and Manuel Vaz-da-Silva and Bruno Igreja and Lyndon Christopher Wright and Am{\'i}lcar Falc{\~a}o and Lu{\'i}s Almeida and Patr{\'i}cio Soares-da-Silva},
  booktitle={Drugs in R&D},
  year={2010}
}
BACKGROUND Activation of the sympathetic nervous system is an important feature in hypertension and congestive heart failure. A strategy for directly modulating sympathetic nerve function is to reduce the biosynthesis of norepinephrine (noradrenaline) via inhibition of dopamine-β-hydroxylase (DβH). OBJECTIVE To assess the safety, tolerability, and pharmacokinetics of etamicastat (BIA 5-453), a new DβH inhibitor, following repeated dosing. METHODS A double-blind, randomized, placebo… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

A rising single oral dose study to investigate the tolerability and pharmacokinetics of etamicastat, a new dopamine beta-hydroxylase inhibitor, in healthy male volunteers [abstract

  • T Nunes, JF Rocha, L Almeida
  • J Clin Pharmacol
  • 2009
Highly Influential
7 Excerpts

Comparative bioavailability study of etamicastat (BIA 5-453) under fasted and fed conditions [abstract

  • A Falcao, T Nunes, JF Rocha
  • J Clin Pharmacol
  • 2009
1 Excerpt

Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics

  • P Gomes, editor
  • Weinheim: Wiley-VCH,
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…